

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.
艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

VOLUNTARY ANNOUNCEMENT
IMMUNE INDICATORS OF THE MRNA SHINGLES/HERPES
ZOSTER VACCINES
WERE SIGNIFICANTLY HIGHER THAN THOSE OF
INTERNATIONAL COMMERCIALY AVAILABLE RECOMBINANT
SUBUNIT VACCINES
APPLICATION FOR CLINICAL TRIAL OF
THE PRODUCT IN THE U.S.

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business developments of the Group.

Following the established corporate strategy, the Group proactively advances the development of the vaccine product pipelines, and leverages the advantages of the mRNA technology platform to accelerate the research and development of mRNA vaccine series products through on-going technological innovation. The application for clinical trial of mRNA shingles/herpes zoster vaccines has been submitted to the U.S. Food and Drug Administration (“**FDA**”) recently, marking a new advancement in the Group’s global strategy.

In preclinical animal testing, results from a third-party testing unit showed that the Group’s mRNA shingles/herpes zoster vaccine specific T-cell immunity, specific IgG antibody titers, and fluorescent antibody to membrane antigen (FAMA) titers were significantly higher than those of international commercially available recombinant subunit control vaccines.

Currently, no mRNA shingles/herpes zoster vaccine has been approved for marketing in the world. The vaccination rate of shingles/herpes zoster vaccine in the target population is only about 0.1%, leaving much room for improvement. In 2024, the global sales of GSK shingles/herpes zoster vaccine reached approximately US\$4.310 billion. According to the forecast of China Insights Industry Consultancy Limited, an industry consultant, it is expected that the market size of shingles/herpes zoster vaccines in China will reach approximately RMB20.0 billion and the global market size will reach approximately US\$23.9 billion by 2030. Upon approval of the product for marketing, it will bring considerable growth to the Group's performance. The mRNA shingles/herpes zoster vaccine is expected to reshape the market landscape due to its advantages in terms of safety and immunogenicity.

The Group is one of the enterprises that takes the lead in developing mRNA vaccine products in China, and also one of the first batch of domestic vaccine enterprises that has obtained an independent patent for mRNA technology. The Group has a mature mRNA vaccine research and development system. The Group has now smoothed the whole life cycle process such as the research, development and production of mRNA vaccines, allowing for rapid achievement of the industrialization of mRNA vaccine products after obtaining clinical approval and accelerating the commercialization process of vaccine products.

By order of the Board
AIM Vaccine Co., Ltd.
Mr. Yan ZHOU

*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, February 23, 2025

As at the date of this announcement, the Board of the Company comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Wen GUAN, Mr. Shaojun JIA and Mr. Jie ZHOU as executive directors; Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Hui OUYANG, Ms. Jie WEN and Mr. Xiaoguang GUO as independent non-executive directors.